Angiosarcoma of the breast gland: molecular genetic profile, diagnosis and treatment

Cover Page

Cite item

Full Text

Abstract

Angiosarcoma is a rare, aggressive tumor arising from the endothelial cells of blood vessels that can affect internal organs, but the most common location is the skin. The article presents current data on the molecular genetic profile, diagnosis and treatment of primary and secondary angiosarcomas of the breast. A search for relevant sources was carried out in the PubMed, Cochrane Library and eLibrary systems, publications from 2012 to 2023 were examined, 29 of which were used to write this review.no standard treatment guidelines, and the optimal approach remains surgical resection to achieve negative resection margins. The role of neoadjuvant, adjuvant chemotherapy and radiotherapy remains controversial.

About the authors

L. N. Lyubchenko

N.A. Lopatkin Research Institute of Urology and Interventional Radiology – branch of the National Medical Research Radiological Center, Ministry of Health of Russia

ORCID iD: 0000-0002-9157-3589

; Bld. 1, 513rd Parkovaya St., Moscow 105425

Russian Federation

E. K. Saribekyan

P.A. Herzen Moscow Research Oncology Institute – branch of the National Medical Research Radiological Center, Ministry of Health of Russia

32nd Botkinskiy Proezd, Moscow 125284

Russian Federation

A. R. Bosieva

P.A. Herzen Moscow Research Oncology Institute – branch of the National Medical Research Radiological Center, Ministry of Health of Russia;
3Russian Peoples’ Friendship University

Author for correspondence.
Email: ms.bosieva@mail.ru
ORCID iD: 0000-0003-0993-8866

Alana Ruslanovna Bosieva

32nd Botkinskiy Proezd, Moscow 125284;
6 Miklukho-Maklaya St., Moscow 117198

Russian Federation

A. D. Zikiryakhodzhaev

P.A. Herzen Moscow Research Oncology Institute – branch of the National Medical Research Radiological Center, Ministry of Health of Russia;
Russian Peoples’ Friendship University;
Sechenov University, Ministry of Health of Russia

ORCID iD: 0000-0001-7141-2502

32nd Botkinskiy Proezd, Moscow 125284;
6 Miklukho-Maklaya St., Moscow 117198;
Bld. 2, 8 Trubetskaya St., Moscow119991

 

Russian Federation

G. L. Buchkin

Sechenov University, Ministry of Health of Russia

Bld. 2, 8 Trubetskaya St., Moscow119991

 

Russian Federation

N. D. Zamaldinov

P.A. Herzen Moscow Research Oncology Institute – branch of the National Medical Research Radiological Center, Ministry of Health of Russia

32nd Botkinskiy Proezd, Moscow 125284

Russian Federation

A. A. Fedenko

P.A. Herzen Moscow Research Oncology Institute – branch of the National Medical Research Radiological Center, Ministry of Health of Russia

ORCID iD: 0000-0003-4927-5585

32nd Botkinskiy Proezd, Moscow 125284

Russian Federation

References

  1. Saribekyan E.K., Bosieva A.R., Medvedev S.V. et al. Postradiative angiosarcoma of the breast: a rare clinical case. Zlokachestvennye opukholi = Malignant Tumors 2023;13(2):7. (In Russ.). doi: 10.18027/2224-5057-2023-13-2-7
  2. Smith T.L., Morris C.G., Mendenhall N.P. Angiosarcoma after breastconserving therapy: long-term disease control and late effects with hyperfractionated accelerated re-irradiation (HART). Acta Oncol 2014;53(2):235–41. doi: 10.3109/0284186X.2013.819117
  3. Ghareeb E.R., Bhargava R., Vargo J.A. et al. Primary and radiationinduced breast angiosarcoma: clinicopathologic predictors of outcomes and the impact of adjuvant radiation therapy. Am J Clin Oncol 2016;39(5):463–7. doi: 10.1097/COC.0000000000000077
  4. Fedenko A.A., Konev A.A., Anurova O.A. et al. Angiosarcomas. Sarkomy kostei, miagkikh tkanei i opukholi kozhi = Bone and Soft Tissue Sarcomas, Tumors of the Skin 2013;1:24–41. (In Russ.).
  5. Mantilla J.G., Koenigsberg T., Reig B. et al. Core biopsy of vascular neoplasms of the breast: pathologic features, imaging, and clinical findings. Am J Surg Pathol 2016;40(10):1424–34. doi: 10.1097/PAS.0000000000000668
  6. Rosen P.P., Kimmel M., Ernsberger D. Mammary angiosarcoma. The prognostic significance of tumor differentiation. Cancer 1988;62(10):2145–51. doi: 10.1002/1097-0142(19881115)62: 10<2145::aid-cncr2820621014>3.0.co;2-o
  7. Wang X.Y., Jakowski J., Tawfik O.W. et al. Angiosarcoma of the breast: a clinicopathologic analysis of cases from the last 10 years. Ann Diagn Pathol 2009;13(3):147–50. doi: 10.1016/j.anndiagpath.2009.02.001
  8. Rohan V.S., Hanji A.M., Patel J.J. et al. Primary angiosarcoma of the breast in a postmenopausal patient. J Cancer Res Ther 2010;6(1):120–2. doi: 10.4103/0973-1482.63543
  9. Strobbe L.J., Peterse H.L., van Tinteren H. et al. Angiosarcoma of the breast after conservation therapy for invasive cancer, the incidence and outcome. An unforseen sequela. Breast Cancer Res Treat 1998;47(2):101–9. doi: 10.1023/a:1005997017102
  10. Brooks T., Hurley L. The role of supercoiling in transcriptional control of MYC and its importance in molecular therapeutics. Nat Rev Cancer 2009;9(12):849–61. doi: 10.1038/nrc2733
  11. West J.G., Weitzel J.N., Tao M.L et al. BRCA mutations and the risk of angiosarcoma after breast cancer treatment. Clin Breast Cancer 2008;8(6):533–7. doi: 10.3816/CBC.2008.n.066
  12. Meyer N., Penn L. Reflecting on 25 years with MYC. Nat Rev Cancer 2008;8(12):976–90. doi: 10.1038/nrc2231
  13. Fraga-Guedes C., André S., Mastropasqua M.G. et al. Angiosarcoma and atypical vascular lesions of the breast: diagnostic and prognostic role of MYC gene amplification and protein expression. Breast Cancer Res Treat 2015;151(1):131–40. doi: 10.1007/s10549-015-3379-2
  14. Manner J., Radlwimmer B., Hohenberger P. et al. MYC high level gene amplification is a distinctive feature of angiosarcomas after irradiation or chronic lymphedema Am J Pathol 176;1:34–9. doi: 10.2353/ajpath.2010.090637
  15. Zietz C., Rossle M., Haas C. et al. MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas. Am J Pathol 1998;153(5):1425–33. doi: 10.1016/S0002-9440(10)65729-X
  16. Naka N., Tomita Y., Nakanishi H. et al. Mutations of p53 tumorsuppressor gene in angiosarcoma. Int J Cancer 1997;71(6):952–5. doi: 10.1002/(sici)1097-0215(19970611)71:6<952::aid-ijc7>3.0.co;2-x
  17. Wei Y., Yang X., Gao L. et al. Differences in potential key genes and pathways between primary and radiation-associated angiosarcoma of the breast. Translati Oncol 2022;19:101385. DOI: 10.1016/j. tranon.2022.101385
  18. West J.G., Weitzel J.N., Tao M.L. et al. BRCA mutations and the risk of angiosarcoma after breast cancer treatment. Clin Breast Cancer 2008;8(6):533–7. doi: 10.3816/CBC.2008.n.066
  19. Kirschner K.M., Sciesielski L.K., Scholz H. Wilms’ tumour protein Wt1 stimulates transcription of the gene encoding vascular endothelial cadherin. Pflugers Arch 2010;460(6):1051–61. doi: 10.1007/s00424-010-0873-6
  20. Wooster R., Weber B.L. Breast and ovarian cancer. N Engl J Med 2003;348(23):2339–47. doi: 10.1056/NEJMra012284
  21. Milne R.L., Osorio A., Ramón y Cajal T. et al. Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 2010;119(1):221–32. doi: 10.1007/s10549-009-0394-1
  22. Easton D.F., Bishop D.T., Ford D., Crockford G.P. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1993;52(4):678–701.
  23. Li Q., Zhang Y., El-Naggar A.K. et al. Therapeutic efficacy of p53 restoration in Mdm2-overexpressing tumors. Mol Cancer Res 2014;12(6):901–11. doi: 10.1158/1541-7786.MCR-14-0089
  24. Lahat G., Dhuka A.R., Hallevi H. et al. Angiosarcoma: clinical and molecular insights. Ann Surg 2010;251(6):1098–106. doi: 10.1097/SLA.0b013e3181dbb75a
  25. Kadouri L., Sagi M., Goldberg Y. et al. Genetic predisposition to radiation induced sarcoma: possible role for BRCA and p53 mutations. Breast Cancer Res Treat 2013;140(1):207–11. doi: 10.1007/s10549-013-2621-z
  26. Wada M., Horinaka M., Yasuda S. et al. PDK1 is a potential therapeutic target against angiosarcoma cells. J Dermatol Sci 2015;78(1):44–50. doi: 10.1016/j.jdermsci.2015.01.015
  27. Stacchiotti S. Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian rare cancer network. Ann Oncol 2012;23(2):501–8. doi: 10.1093/annonc/mdr066
  28. Pervaiz N. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer.2008;113(3):573–81. doi: 10.1002/cncr.23592
  29. Woll P.J. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected softtissue sarcoma (EORTC 62931): a multicentre randomized controlled trial. Lancet Oncol 2012;13(10):1045–54. doi: 10.1016/S1470-2045(12)70346-7
  30. Suzuki Y., Taniguchi K., Hatono M. et al. Recurring radiationinduced angiosarcoma of the breast that was treated with paclitaxel chemotherapy: a case report. Surg Case Rep 2020;6(1):25. doi: 10.1186/s40792-020-0790-7

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Lyubchenko L.N., Saribekyan E.K., Bosieva A.R., Zikiryakhodzhaev A.D., Buchkin G.L., Zamaldinov N.D., Fedenko A.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС77-66671 от  09.11.2009.